Clonal variability in CD95 expression is the major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line

Leukemia

Volumn 14, Issue 5, 2000, Pages 830-840

  Shain, K H ^a   Landowski, T H ^a,c   Buyuksal, I ^a,c   Cantor, A B ^b   Dalton, W S ^a,b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Apoptosis; CD59 Fas APO 1; Chemotherapy; Clonal variability; Drug resistance; Multiple myeloma

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; VINCRISTINE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CLONE; CELL DEATH; CELL HETEROGENEITY; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0034105898     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401776     Document Type: Article

References (43)

1. Itoh N, Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-10937.
2. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel Mort1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803-315.
4. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
5. Muzio M. Signalling by proteolysis: death receptors induce apoptosis. Int J Clin Lab Res 1998; 28: 141-147.
6. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin K-M, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 6: 1675-1687.
7. Zou H, Li Y, Liu X, Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549-11556.
8. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
9. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-292.
10. Sato T, Irie S, Kitada S, Reed JC. FAP-1 : a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-415.
11. Zhou YW, Komada V, Inaba H, Azuma E, Sakurai M. Down-regulation of Fas-associated phosphatase-1 (FAP-1) in interleukin-2-activated T cells. Cell Immunol 1998; 186: 103-110.
12. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741-1749.
13. Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoli T, Sawa E, Nishitoba T, Kamishohara M, Kobayashi E, Kataoka S, Sato T. The molecular interaction of Fas and FAP-1 : a tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 1997; 272: 8539-8545.
14. Reed JC. The Bcl-2 family of proteins. Oncogene 1999; 17: 3225-3236.
15. 1 can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci USA 1997; 94: 3759-3764.
16. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Pong T, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
17. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
18. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935-943.
19. Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
20. Antoku K, Liu Z, Johnson DE. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia 1997; 11: 1665-1672.
21. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58: 4453-4460.
22. Landowski TH, Shain KH, Oshiro MM, Buyuksal I, Painter JS, Dalton WS. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood 1999; 94: 265-274.
23. Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-1/fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
24. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas mediated apoptosis. Blood 1997; 89: 1180-1187.
25. Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 12: 3466-3576.
26. Nishiuchi R, Yoshino T, Matsuo Y, Sakuma I, Cao L, Seino Y, Takahashi K, Akagi T. The Fas antigen is detected on immature B cells and the representative cell lines show Fas-mediated apoptosis. Br J Haematol 1996; 92: 302-307.
27. Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ, Peter ME, Offringa R, Krammer PH. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol 1997; 27: 3492-3498.
28. Martins LM, Kottke TJ, Kaufmann SH, Earnshaw WC. Phosphorylated forms of activated caspases are present in cytosol from HL-60 cells during etoposide-induced apoptosis. Blood 1998; 92: 3042-3049.
29. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
30. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 1999; 398: 777-785.
31. Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 1998; 140: 171-182.
32. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999; 274: 7987-7992.
33. Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Pineiro A, Naval J. Doxorubicin-induced apoptosis in human T cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360-364.
34. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 1999; 93: 3053-3063.
35. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57: 3331-3334.
36. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-5060.
37. Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (Fas/APO-1) in leukaemia-lymphoma toumor lines. Br J Haematol 1997; 96: 584-593.
38. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 3: 757-764.
39. Hua C, Zorn S, Jensen JP, Coupland RW, Ko HS, Wright JJ, Bakhshi A. Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene. Oncogene Res 1988; 2: 263-275.
40. McDonnell TJ, Nunez G, Platt FM, Hockenberry D, London L, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 1990; 10: 1901-1907.
41. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
42. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
43. Tillman DM, Harwood FG, Gibson AA, Houghton JA. Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Diff 1998; 5: 450-457.